5,789 Shares in Glaukos Co. (NYSE:GKOS) Acquired by Williamson Legacy Group LLC

Williamson Legacy Group LLC purchased a new position in Glaukos Co. (NYSE:GKOS) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 5,789 shares of the medical instruments supplier’s stock, valued at approximately $868,000.

Other hedge funds also recently modified their holdings of the company. IFP Advisors Inc bought a new stake in shares of Glaukos in the 4th quarter worth approximately $43,000. Asset Planning Inc bought a new stake in shares of Glaukos in the 4th quarter worth approximately $90,000. Harvest Fund Management Co. Ltd raised its holdings in shares of Glaukos by 2,263.2% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 860 shares during the period. KBC Group NV raised its holdings in shares of Glaukos by 16.2% in the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock worth $188,000 after purchasing an additional 201 shares during the period. Finally, EWA LLC bought a new stake in shares of Glaukos in the 3rd quarter worth approximately $209,000. Institutional investors own 99.04% of the company’s stock.

Glaukos Stock Performance

NYSE GKOS opened at $119.87 on Friday. Glaukos Co. has a 52-week low of $83.90 and a 52-week high of $163.71. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The company has a market capitalization of $6.61 billion, a P/E ratio of -41.77 and a beta of 1.04. The company has a fifty day moving average of $150.84 and a 200-day moving average of $139.31.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). The company had revenue of $105.50 million for the quarter, compared to the consensus estimate of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. As a group, equities research analysts predict that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on GKOS shares. Needham & Company LLC lifted their price target on shares of Glaukos from $149.00 to $176.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Truist Financial lifted their price objective on shares of Glaukos from $152.00 to $185.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Stifel Nicolaus lifted their price objective on shares of Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, December 31st. Mizuho upgraded shares of Glaukos from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $140.00 to $200.00 in a research note on Wednesday, February 19th. Finally, Citigroup upgraded shares of Glaukos from a “neutral” rating to a “buy” rating and boosted their price target for the company from $132.00 to $162.00 in a research report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $163.25.

Insiders Place Their Bets

In other Glaukos news, insider Tomas Navratil sold 3,416 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the sale, the insider now directly owns 72,437 shares of the company’s stock, valued at $10,658,380.18. The trade was a 4.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Joseph E. Gilliam sold 3,328 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $149.85, for a total transaction of $498,700.80. Following the transaction, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at approximately $15,310,024.65. This trade represents a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 18,744 shares of company stock valued at $2,792,151 over the last three months. Insiders own 6.40% of the company’s stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.